162 related articles for article (PubMed ID: 10599773)
1. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
3. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
4. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
5. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
6. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
9. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
10. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
[TBL] [Abstract][Full Text] [Related]
11. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Gélinas I; Gauthier S; Cyrus PA
J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
15. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S
Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
18. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
20. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
